PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy

The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).

NCT Number	NCT05055648
Lead Sponsor	University of Aarhus Collaborators: University of Leeds, KU Leuven, University College, London, Aarhus University Hospital, Technische Universität Dresden, Academisch Ziekenhuis Groningen, CNAO National Center of Oncological Hadrontherapy, Agenzia Nazionale per i Servizi Sanitari Regionali, Centre Antoine Lacassagne, Centre Leon Berard, Institut Curie, Maastro Clinic, The Netherlands, University College London Hospitals, The Christie NHS Foundation Trust, Paul Scherrer Institut, Center for Proton Therapy, HollandPTC, IBA worldwide, Varian- A Siemens Healthineer Company
Conditions	Esophageal Cancer, Radiotherapy, Side Effect, Proton Therapy
Enrollment	396 participants
Start Date	2022-05-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2032-12-01 (estimated)
Updated on ClinicalTrials.gov	2024-12-17